https://www.selleckchem.com/pr....oducts/n-formyl-met-
missing data problem in the per-protocol analysis, and covariate imbalance between treatment arms in the as-treated analysis. Moreover, insurance denial forces the critical appraisal of patient features (eg, age) affected by the denial and potentially influencing clinical success. In the presence of insurance denial, our study suggests cautious reporting of ITT and as-treated analyses, and placing primary emphasis on the results of the per-protocol analysis. The scope of radiation therapy is limited in melanoma. Using
Curtir
Comentario
Compartilhar
